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INTRODUCTION
Lysosomal acid lipase deficiency (LALD; OMIM 278000; ref. 1) 
is an autosomal-recessive disorder caused by mutations of the 
LIPA gene located on chromosome 10q23.2-q23.3.2 Lysosomal 
acid lipase (LAL) is essential for the breakdown of cholesteryl 
esters and triglycerides in the lysosomes, and deficiency of LAL 
results in accumulation of these lipids in the tissues of affected 
individuals.1,3 The disease presents across an age continuum, 
from infants to adults, with common features including hepa-
tomegaly, elevated serum transaminase concentrations, and 
progressive liver fibrosis and cirrhosis.4–7 In infants, growth fail-
ure (GF) and rapidly progressive hepatic disease are prominent 
features of LALD (historically known as Wolman disease) and 
key contributors to mortality, with death typically occurring 
within the first 6 months of life.2,8–10
Clinical familiarity with LALD is low, and many aspects of 
its clinical presentation, progression, and medical management 
are poorly understood. In addition, systematic analysis of the 
presentation of LALD in infants is lacking; current descrip-
tions are largely based on case reports and small case series, 
many from more than 30 years ago.5–7,11,12 Medical records of 
infants with confirmed LALD were systematically reviewed to 
develop a more detailed understanding of the clinical manifes-
tations and course of LALD presenting in infancy, including 
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Purpose: The purpose of this study was to enhance understanding of 
lysosomal acid lipase deficiency (LALD) in infancy.
Methods: Investigators reviewed medical records of infants with 
LALD and summarized data for the overall population and for 
patients with and without early growth failure (GF). Kaplan–Meier 
survival analyses were conducted for the overall population and for 
treated and untreated patients.
Results: Records for 35 patients, 26 with early GF, were analyzed. 
Prominent symptom manifestations included vomiting, diarrhea, 
and steatorrhea. Median age at death was 3.7 months; estimated 
probability of survival past age 12 months was 0.114 (95% confidence 
interval (CI): 0.009-0.220). Among patients with early GF, median 
age at death was 3.5 months; estimated probability of survival past 
age 12 months was 0.038 (95% CI: 0.000-0.112). Treated patients 
(hematopoietic stem cell transplant (HSCT), n = 9; HSCT and liver 
transplant, n = 1) in the overall population and the early GF subset 
survived longer than untreated patients, but survival was still poor 
(median age at death, 8.6 months).
Conclusions: These data confirm and expand earlier insights on the 
progression and course of LALD presenting in infancy. Despite varia-
tions in the nature, onset, and severity of clinical manifestations, and 
treatment attempts, clinical outcome was poor.
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characterization of patient survival, to provide data to serve as a 
historical reference for efficacy studies of this population.
MATERIALS AND METHODS
Study design, patients, and data collection
Initial study site selection was based on the completion of a fea-
sibility questionnaire sent to ~500 physicians in 44 countries. 
A total of 154 physicians responded, and all physicians identi-
fied as being involved in the care of patients with LALD were 
considered for participation; site selection was based on will-
ingness to participate.
The study protocol and other documents were reviewed by 
an institutional review board or equivalent body before study 
site initiation, and informed consent was obtained if required 
by local regulations. Eligibility for inclusion required a clinical 
diagnosis of LALD within the first 2 years of life―confirmed 
by either LAL enzyme activity testing or LIPA gene mutational 
analysis―and the availability of the following in their medical 
records: date of birth; sex; date of death or age at time of death 
if deceased; weight at birth (or first recorded weight) plus at 
least one weight obtained ≥4 weeks later but before initiation of 
any treatment with curative intent; test date, result, and name 
of testing center for LAL enzyme activity or LIPA gene muta-
tional analysis; and date of initiation of hematopoietic stem cell 
transplant (HSCT) or liver transplant procedure, if applicable 
(defined as the first day of any pretransplant conditioning, if 
available). Additional data collected when available included 
method of diagnosis, demographics, clinical and family history, 
anthropometric measurements, physical examination find-
ings, clinical chemistry results (including assessments of adre-
nal function, hematologic tests, and CD4-to-CD8 ratio), liver 
biopsy data, imaging findings, details of any supportive inter-
ventions (e.g., nutritional support including use of parenteral 
nutrition, blood transfusions), and autopsy results.
Data analysis
Enrollment of approximately 40 patients with LALD presenting 
in infancy (i.e., before age 2 years) was expected to provide a rea-
sonable description of the clinical presentation and outcomes 
of this rare disease.13 Continuous end points were summarized 
as the number of patients with nonmissing values, mean, SD, 
minimum, maximum, median, first quartile, and third quartile. 
Categorical end points were summarized as frequencies and/
or using shift tables. Anthropometric data, including weight, 
length, head circumference, weight for length, and body mass 
index, were standardized to z-scores according to  age/sex-nor-
mative data gathered by the World Health Organization14,15 and 
summarized as continuous data. Percentiles were computed 
from the z-scores. Anthropometric data were also represented 
as the number and percentage of patients meeting criteria for 
being underweight, defined as ≤2 SDs below the median weight 
for age. With the exception of survival data, data for patients 
who received a transplant were summarized only through the 
date of initiation of any pretransplant conditioning regimen, if 
available; otherwise, the date of transplant was used.
Because of the prominence of GF in the first 6 months of 
life in patients with LALD and the plausible link between this 
aspect of the disease and mortality, analyses were performed 
for the overall population and for the subset of patients who 
fulfilled defined early GF criteria similar to those used in an 
ongoing clinical trial of enzyme replacement therapy in infants 
with LALD (www.clinicaltrials.gov identifier NCT01371825). 
Early GF was defined as fulfillment of one or more of the 
following criteria before age 6 months: (i) decreased body 
weight across ≥2 of the 11 major percentiles on a standard 
World Health Organization weight-for-age chart; (ii) body 
weight (in kilograms) below the 10th percentile on a stan-
dard World Health Organization weight-for-age chart and no 
weight gain for the previous 2 weeks; and (iii) loss of ≥5% of 
birth weight in children >2 weeks of age. As appropriate, sum-
mary statistics and statistical analyses also were performed for 
treated (i.e., those who received liver transplant or HSCT) and 
untreated patients.
Time from birth to death and proportions of patients alive 
at selected ages were estimated using Kaplan–Meier method-
ology. Estimates of the median (with exact 95% confidence 
intervals) and upper and lower quartiles of time to death were 
derived and plotted. Time-to-event analyses were conducted 
for all eligible patients with evaluable data and for the subsets 
of patients with and without early GF. For each analysis, a stan-
dard life table of time to death was created for the overall pop-
ulation and for treated (i.e., received transplant) and untreated 
patients. Time to death in treated and untreated patients was 
compared using log-rank tests. A multivariate Cox propor-
tional hazard regression analysis model was used to examine 
the effect of the following covariates on survival: sex, country 
of origin, transplant, blood transfusion, enteral supplementa-
tion, parenteral supplementation, and steroid therapy. No data 
imputation was planned or conducted.
RESULTS
Population
Forty patients who received a clinical diagnosis of “Wolman 
disease” between 1985 and 2012 were enrolled. Four were ineli-
gible because they lacked a confirmed diagnosis (n = 2) or a 
second weight measurement (n = 2). In addition, one patient 
was excluded from this analysis because he was later enrolled in 
a separate clinical study.
There were 35 patients in the overall population, enrolled 
from 17 centers in 6 countries. Of these patients, 26 were clas-
sified as having early GF. Baseline demographic characteristics 
and clinical/family histories are shown in Table 1. Most patients 
(70%) who received transplant were from the United States. 
LALD was diagnosed by enzyme activity testing in 34 patients 
(97%). Homozygous mutations were reported for 3  of the 
12 patients who had LIPA mutation analysis performed. Two 
siblings (twins) had identical null mutations arising from a pre-
mature stop codon (TAT>TAG) at exon 298; all other patients 
had unique mutations. No patients had a copy of the exon 8 
splice junction mutation (c.894G>A).
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Symptom onset and disease presentation
Overall, 43% of patients had first symptom onset before the age 
of 1 month. Median ages at first symptom onset were similar for 
the subsets with and without early GF (1.1 month (range: 0.0–
3.0 months) and 1.0 month (range: 0.23–6.0 months), respec-
tively). Prominent manifestations included vomiting, diarrhea, 
and steatorrhea, accompanied by liver biochemical abnor-
malities. The median time interval between symptom onset 
and diagnosis was 1.2 months (range: 0.05–17.0 months). The 
median age at diagnosis was lower among patients with early 
GF than among those without early GF (2.5 months (range: 
1.0–5.0 months) and 5.0 months (range: 1.0–17.7 months), 
respectively).
Growth failure
Weight-for-age z-scores were low before diagnosis (overall: 
mean, −2.09; median, −2.64; early GF: mean, −1.98; median, 
−2.55) and worsened with disease progression, decreasing from 
the first record to death by a mean of −1.98 (median: −1.75) in 
the overall population and by a mean of −2.40 (median: −2.72) 
in the early GF subgroup. The percentage of underweight 
patients increased over time in the overall population (20, 54, 
and 66% at first record, diagnosis, and death, respectively).
Liver biochemical findings
Median alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) concentrations in the overall population 
were elevated at diagnosis (56.5 U/l (0.94 μkat/l; n  =  24) and 
151 U/l (2.52 μkat/l; n = 19), respectively). At diagnosis, ALT 
concentration was abnormal in 14 of 24 patients, including 
8 patients who had ALT values more than three times the upper 
limit of normal. Median ALT values substantially increased 
with disease progression in patients with and without early GF 
(Figure 1a). Median ALT concentration at death (or last mea-
surement) in the overall population was 110.5 U/l (1.85 μkat/l; 
range: 13–851 U/l (0.22–14.21 μkat/l); n = 20). Similarly, AST 
concentrations were elevated at diagnosis in 18 of 19 patients, 
and AST concentrations increased with disease progression. 
Median AST concentration at death (or last measurement) was 
283 U/l (4.73 μkat/l; range: 35–4,250 U/l (0.58–70.97 μkat/l); 
n  =  26). γ-Glutamyl transferase concentrations were elevated 
at diagnosis in 11 of 13 patients, and γ-glutamyl transferase 
concentrations increased after diagnosis in 10 of 12 patients 
with available values. Total bilirubin concentrations at diagno-
sis were elevated in 11 patients (52%), of which 8 patients had 
bilirubin more than three times the upper limit of normal; the 
other 10 patients had bilirubin concentrations that were normal 
Table 1 Baseline demographic characteristics and clinical/family history
With early  
GF (n = 26)
Without early  
GF (n = 9)
Overall population
Untreated (n = 25) Treateda (n = 10) All (N = 35)
Sex
  Male 13 (50) 6 (67) 13 (52) 6 (60) 19 (54)
  Female 13 (50) 3 (33) 12 (48) 4 (40) 16 (46)
Race
  Asian 8 (31) 0 8 (32) 0 8 (23)
  White 10 (38) 7 (78) 9 (36) 8 (80) 17 (49)
  Other 4 (15) 1 (11) 4 (16) 1 (10) 5 (14)
  Unknown 4 (15) 1 (11) 4 (16) 1 (10) 5 (14)
Ethnicity
  Hispanic/Latino 2 (8) 1 (11) 2 (8) 1 (10) 3 (9)
  Not Hispanic/Latino 19 (73) 7 (78) 18 (72) 8 (80) 26 (74)
  Unknown 5 (19) 1 (11) 5 (20) 1 (10) 6 (17)
Consanguinityb
  Yes 15 (58) 2 (22) 14 (56) 3 (30) 17 (49)
  No 8 (31) 4 (44) 8 (32) 4 (40) 12 (34)
  Unknown 3 (12) 3 (33) 3 (12) 3 (30) 6 (17)
Sibling with LALD
  Yes 11 (42) 1 (11) 11 (44) 1 (10.0) 12 (34)
  No 14 (54) 4 (44) 12 (48) 6 (60) 18 (51)
  Unknown 1 (4) 4 (44) 2 (8) 3 (30) 5 (14)
Values are represented as no. (%).
GF, growth failure; HSCT, hematopoietic stem cell transplant; LALD, lysosomal acid lipase deficiency.
aTreated refers to patients who received HSCT and/or liver transplant. bParents of the patient were blood relatives.
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(n = 9) or below normal (n = 1). Worsening of bilirubin concen-
trations over time was noted in some patients, and no patient 
shifted to a less severe bilirubin category (Figure 1b).
Of the four patients who had unique prothrombin time mea-
surements at both diagnosis and death, the median change was 
1.2 s (range: −3.6 to 2.8 s). Of the four patients who had unique 
partial thromboplastin time measurements at both diagnosis 
and death, the median change was 7.0 s (range: 0.4–39.9 s).
Median serum albumin concentration was low at diagnosis 
(26.0 g/l; range: 15–36 g/l; n = 22). In the eight patients who had 
unique serum albumin measurements both at diagnosis and at 
death, the median change was −0.5 g/l (range: −9 to 21 g/l).
Pathology findings
Liver biopsies were performed in nine patients at a median 
age of 5.2 months (range: 1.5–43.9 months). All nine patients 
had evidence of fibrosis (n = 6) and/or steatosis/lipid vacu-
oles (n = 6). Autopsy reports were available for five patients. 
Liver enlargement and spleen enlargement were evident in 
four and five patients, respectively; reports included yellow-
orange discoloration, fatty infiltration/steatosis, necrosis, 
fibrosis, and cirrhosis. Adrenal abnormalities, including 
enlargement, necrosis, and microcalcifications, were noted 
in all five cases.
Lipid biochemistry
Median total cholesterol concentrations were normal at diag-
nosis (2.99 mmol/l; range: 1.54–4.58 mmol/l; n = 16). Marked 
hypercholesterolemia (total cholesterol >5.17 mmol/l) occurred 
in two patients who did not have early GF, showed no clinical 
evidence of failure to thrive, and survived >12 months before 
receiving transplant. Median triglyceride concentration was 
elevated at diagnosis (2.43 mmol/l; range: 1.3–6.0 mmol/l; 
n  =  15). High-density lipoprotein cholesterol levels were low 
at diagnosis, with 67% of patients having high-density lipo-
protein cholesterol values <50% of the lower limit of normal 
at diagnosis.
Imaging findings
Among 34 patients who had at least one abdominal imaging 
procedure, 27 (79%) had adrenal calcification (including 15 on 
X-ray). Hepatomegaly and/or splenomegaly were noted in 27 
patients.
Supportive interventions and other treatments
Thirty-three patients (94%) in the overall population received 
a supportive intervention, which most commonly included 
nutritional support (n = 25, 71%) or blood transfusions (n = 22, 
63%). Blood transfusions were reported by a similar propor-
tion of patients with early GF and those without early GF. 
Nutritional support most often involved the administration of 
enteral (46%) or parenteral (49%) supplements. Steroid therapy 
was administered to five patients (14%), though there was no 
evidence of adrenal insufficiency per an adrenal function test.
Ten patients (29%) received HSCT. The median age at treat-
ment was 5.4 months (range: 2.2–45.0 months), with most 
(7/10) patients receiving treatment before age 12 months. 
Five patients with early GF received treatment, all within the 
first 8 months of life. Only three patients had HSCT after age 
12 months (at ages 19, 35, and 45 months). One patient who 
received a bone marrow transplant at age 35.1 months and 
died at age 37.3 months had received a liver transplant at age 
4.1 months.
Survival
Although the protocol allowed for enrollment of living patients, 
all patients in the overall population were deceased at enroll-
ment. The median age at death was 3.7 months (range: 1.4–46.3 
months), and the Kaplan–Meier estimate for the probability 
of survival past age 6 months was 0.257 (Figure 2a, Table 2). 
Only four patients (one with early GF, three without early GF) 
survived beyond age 12 months. Two of these patients had 
undergone HSCT (surviving to ages 46.3 and 26.9 months) and 
one underwent liver transplant and HSCT (surviving to age 
37.3 months). The remaining patient (without early GF) was 
Figure 1  Spaghetti plot of (a) alanine aminotransferase (ALT) and (b) bilirubin changes over time in infants with lysosomal acid lipase deficiency.
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untreated and survived to age 19.3 months. The Kaplan–Meier 
estimate for probability of survival past age 12 months was 
0.114 (Figure 2a, Table 2). Log-rank test results suggested that, 
although all patients died prematurely, treated patients survived 
significantly longer (P < 0.001; median age at death, 8.6 months; 
range: 2.6–46.3 months) than did untreated patients (median 
age at death: 3.0 months; range: 1.4–19.3 months).
Among patients with early GF, the median age at death (3.5 
months; range: 1.4–37.3 months) was similar to that of the over-
all population; however, Kaplan–Meier estimates for survival to 
ages 6 and 12 months were lower (Figure 1b, Table 2). This dif-
ference was largely attributable to the long survival duration of 
three patients without early GF, including one untreated patient 
who survived to 19.3 months and two treated patients who sur-
vived to ages 26.9 months and 46.3 months. Patients with early 
GF who received transplant had modest but significantly longer 
survival than did untreated patients with early GF (P = 0.008). 
Among untreated patients with early GF, the probability of sur-
vival past age 6 months was lower still, and an estimated zero 
probability of survival past age 12 months was predicted in this 
group (Table  2). Kaplan–Meier survival estimates in patients 
without early GF were greater than those of the overall popula-
tion, and survival did not differ significantly between treated 
and untreated patients (P = 0.14).
In a Cox proportional hazard regression analysis model for 
the overall population, country of origin, treatment, enteral 
supplementation, and parenteral supplementation were asso-
ciated with reduced risk of death (Supplementary Table S1 
online).
DISCUSSION
These data confirm and expand earlier insights on the rapidly 
progressive and fatal course of LALD presenting in infants and 
provide a more comprehensive understanding of disease pro-
gression and factors that might influence the disease course. 
Clinical presentation with diarrhea, vomiting, abdominal dis-
tension, and hepatosplenomegaly was common early in life and 
is consistent with previous descriptions of LALD in infants.4–7 
Undernourishment with loss of subcutaneous fat and muscle 
was noted as a prominent feature in early case reports of infants 
with LALD,5,7 and a review of published cases performed before 
initiation of this study suggested that early GF might be a sensi-
tive and specific marker for risk of rapid disease progression 
and early death. In this study weight-for-age z-scores were low 
at birth/first record and worsened with disease progression. 
Although only 20% of patients were underweight at birth/first 
record, >50% of patients were underweight by the time of diag-
nosis (median age at diagnosis: 2.6 months). These findings 
confirm that early GF is a prominent manifestation of LALD 
presenting during infancy.
Liver biochemical abnormalities were present early in the 
disease course, with 58 and 95% of patients having elevations in 
ALT and AST concentrations at diagnosis, respectively. Some 
patients showed marked, rapid, progressive increases in serum 
transaminase concentrations over time, accompanied by other 
Figure 2 Kaplan–Meier plot of time from birth to death in the (a) overall population and (b) infants with early growth failure. Top line is “Upper 95% 
Confidence Limit”, Middle line is “Survival Function Estimate” and bottom line is “Lower 95% Confidence Limit”.
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Table 2 Survival estimates by population subgroups
Group or subgroup
Kaplan–Meier estimate (95% CI) for 
probability of survival
≥6 months ≥12 months
Overall population 
(N = 35)
0.257 (0.112-0.402) 0.114 (0.009-0.220)
Early GF (n = 26) 0.154 (0.015-0.293) 0.038 (0.000-0.112)
Non−early GF (n = 9) 0.556 (0.231-0.880) 0.333 (0.025-0.641)
Treateda (n = 10) 0.700 (0.416-0.984) 0.300 (0.016-0.584)
Untreatedb (n = 25) 0.080 (0.00-0.186) 0.040 (0.000-0.117)
Early GF treateda (n = 5) 0.600 (0.171-1.000) 0.200 (0.000-0.551)
Early GF untreatedb  
(n = 21)
0.048 (0.000-0.139) 0.000 (0.000-0.000)
Non−early GF treateda 
(n = 5)
0.800 (0.449-1.000) 0.400 (0.000-0.829)
Non−early GF 
untreatedb (n = 4)
0.250 (0.000-0.674) 0.250 (0.000-0.674)
CI, confidence interval; GF, growth failure.
a“Treated” refers to patients who received hematopoietic stem cell transplant and/or 
liver transplant. b“Untreated” refers to patients who did not receive hematopoietic 
stem cell transplant or liver transplant.
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indicators of progressive liver injury and dysfunction, includ-
ing elevated total bilirubin concentrations, abnormal coagu-
lation values, and depressed serum albumin concentrations. 
These findings suggest that rapidly progressive liver disease 
with hepatocellular failure is likely an important contributor to 
overall mortality in infants presenting with LALD.
Consistent with previously published findings,5–7 fibrosis 
and lipid accumulation in the liver were common in this study. 
Fibrosis was noted in six of the nine patients who underwent 
liver biopsy and was found in four of these patients before age 
6 months and in one patient as early as age 1.5 months. The lim-
ited number of biopsies may reflect the risk associated with the 
liver biopsy procedure in these critically ill infants. In addition, 
although rapidly progressive liver disease contributes to mor-
tality in infants with LALD, the complications of portal hyper-
tension and esophageal varices that often occur in children and 
adults with LALD4 were not prominent in this study, which 
may relate to the rapidity of disease progression in infants.
In this study total cholesterol levels were generally normal, 
and, although triglyceride concentrations were elevated in most 
patients with available data, these abnormalities were generally 
twice the upper limit of normal or less. Although there was evi-
dence of low high-density lipoprotein cholesterol levels in this 
study, data on low-density lipoprotein cholesterol levels were 
very limited but did not show marked abnormalities. These 
findings are consistent with the lipid abnormalities described 
in previous reports.5,11,16
The prognosis for infants presenting with LALD is extremely 
poor. Median age at death was 3.7 months, inclusive of patients 
receiving HSCT, and all but four patients were deceased by age 
9  months. For the overall population, the Kaplan–Meier esti-
mate of the probability of survival past age 12 months was 0.114, 
and transplant was associated with only modest improvement 
in survival; median ages at death were 8.6 months in treated 
patients and 3.0 months in untreated patients. Clinical outcome 
was particularly poor among untreated patients with early GF, 
for whom the Kaplan–Meier estimate for probability of survival 
past age 6 months was 0.048 and zero probability of survival 
beyond age 12 months was predicted. Notably, the median age 
at treatment (5.4 months) exceeded the median age at death in 
the overall population (3.7 months), which suggests a possible 
bias toward transplant in patients with less rapidly progressive 
disease.
Although survival beyond 3 years has been reported for 
three patients diagnosed with Wolman disease who received 
HSCT,17,18 most HSCT attempts have resulted in early death.8,18–20 
In infants, LALD is a progressive disease and usually fatal before 
6 months of age, with or without active treatment. Liver com-
plications in infants with LALD resemble those seen in affected 
children and adults, with hepatomegaly, elevated transaminase 
concentrations, liver steatosis, and fibrosis. This comprehen-
sive characterization of the presentation and clinical course of 
LALD in infants should prove valuable to clinicians, could help 
prevent diagnostic delays, and may serve as a historical control 
for studies of emerging therapeutic interventions.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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